The estimated Net Worth of Justin A Renz is at least $3.87 Milion dollars as of 20 August 2024. Mr Renz owns over 5,289 units of Ardelyx Inc stock worth over $1,759,732 and over the last 10 years he sold ARDX stock worth over $1,712,875. In addition, he makes $394,739 as CFO & Chief Accounting Officer at Ardelyx Inc.
Mr has made over 21 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,289 units of ARDX stock worth $30,994 on 20 August 2024.
The largest trade he's ever made was selling 225,000 units of Ardelyx Inc stock on 26 December 2023 worth over $1,431,000. On average, Mr trades about 10,638 units every 104 days since 2014. As of 20 August 2024 he still owns at least 295,257 units of Ardelyx Inc stock.
You can see the complete history of Mr Renz stock trades at the bottom of the page.
Justin A. Renz CPA, MST, M.S.T., MBA is the CFO & Chief Accounting Officer at Ardelyx Inc.
As the CFO & Chief Accounting Officer of Ardelyx Inc, the total compensation of Mr MBA at Ardelyx Inc is $394,739. There are 5 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
Mr MBA is 49, he's been the CFO & Chief Accounting Officer of Ardelyx Inc since . There are 18 older and 1 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Justin's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: